ArticleInternational journal of legal medicine2019
Post-mortem in situ stability of serum markers of cerebral damage and acute phase response.
Article in International journal of legal medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 29 citations in OpenAlex.
- Article
- Copper and cuproptosis-related genes as indictors for the diagnosis of injury time in traumatic brain injury: human cases and animal experiment.Frontiers in cellular neuroscience · 2026Article
- Machine learning helps predict early onset psychosis with serum protein biomarkers, neuropsychometry, and clinicodemographic data.Scientific reports · 2025Article
- Variance in intraindividual stability of vitreous humor for thanatochemistry.International journal of legal medicine · 2025Article
- Cardiac-specific troponin-I (cTnI) in a post-mortem setting.International journal of legal medicine · 2025Article
- Postmortem biochemistry of GFAP, NSE and S100B in cerebrospinal fluid and in vitreous humor for estimation of postmortem interval: a pilot study.Forensic science, medicine, and pathology · 2025Article
- Advances and Challenges in Traumatic Brain Injury from a Forensic Perspective.Current neuropharmacology · 2025Review
- Post-mortem utility of Neuron Specific Enolase (NSE) and Calcium Binding Protein B (S100B) for differentiating traumatic brain injury from other causes of death.International journal of legal medicine · 2025Article
- Article
- Intralipid as a matrix additive for evaluating hyperlipidemic postmortem blood.Journal of analytical toxicology · 2023Article
- Analysis of the risk of traumatic brain injury and evaluation neurogranin and myelin basic protein as potential biomarkers of traumatic brain injury in postmortem examination.Forensic science, medicine, and pathology · 2022Article
- Forensic biomarkers of lethal traumatic brain injury.International journal of legal medicine · 2022Review
- Post-Mortem Microbiology: Retrospective Analysis of Infections Caused byPathogens (Basel, Switzerland) · 2022Article
- GFAP positivity in neurons following traumatic brain injuries.International journal of legal medicine · 2021Article
- Assessing Protein Biomarkers to Detect Lethal Acute Traumatic Brain Injuries in Cerebrospinal Fluid.Biomolecules · 2021Article
- Dismembered porcine limbs as a proxy for postmortem muscle protein degradation.International journal of legal medicine · 2021Article
- Deaths associated with newly launched SARS-CoV-2 vaccination (Comirnaty®).Legal medicine (Tokyo, Japan) · 2021Article
- Forensic Biochemical Markers to Evaluate the Agonal Period: A Literature Review.Molecules (Basel, Switzerland) · 2021Review
- Persistence of SARS-CoV-2 Viral RNA in Nasopharyngeal Swabs after Death: An Observational Study.Microorganisms · 2021Article
- CircSLC8A1 and circNFIX can be used as auxiliary diagnostic markers for sudden cardiac death caused by acute ischemic heart disease.Scientific reports · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of the given study was to test the in situ stability of biochemical markers of cerebral damage and acute phase response in the early post-mortem interval to assess their usability for forensic pathology. A monocentric, prospective study investigated post-mortem femoral venous blood samples at four time points obtained within 48 h post-mortem starting at the death of 20 deceased, using commercial immunoassays for the ten parameters: S100 calcium-binding protein B (S100B), glial fibrillary acidic protein (GFAP), neuron-specific enolase (NSE), brain-derived neurotrophic factor (BDNF), interleukin-6 (IL-6), C-reactive protein (CRP), procalcitonin (PCT), ferritin, soluble tumor necrosis factor receptor type 1 (sTNFR1), and lactate dehydrogenase (LDH). Significant changes in serum levels were observed only later than 2 h after death for all markers. Inter-laboratory comparability was high, and intra-assay precision was sufficient for most markers. Most of the biomarker levels depended on the severity of hemolysis and lipemia but were robust against freeze-thaw cycles. Serum levels increased with longer post-mortem intervals for S100B, NSE, ferritin, sTNFR1, and LDH (for all p < 0.001) but decreased over this period for CRP (p = 0.089) and PCT (p < 0.001). Largely unchanged median values were found for GFAP (p = 0.139), BDNF (p = 0.106), and IL-6 (p = 0.094). Serum levels of CRP (p = 0.059) and LDH (p = 0.109) did not differ significantly between the final ante-mortem (resuscitation) and the first post-mortem sample (moment of death). Collecting the post-mortem blood sample as soon as possible will reduce the influence of post-mortem blood changes. Serum GFAP for detection of cerebral damage as well as serum IL-6 and CRP as proof of acute phase response seemed to be preferable due to their in situ stability in the first 2 days after death.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.